High-dose firmanertinib with other drugs for EGFR-mutant lung cancer spread to the brain lining
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a targeted therapy (firmanertinib), a biologic drug that blocks blood vessel growth (bevacizumab), and a chemotherapy given into the spinal fluid (pemetrexed) for people with non-small cell lung cancer that has spread to the membranes around the brain (leptomeningeal metastasis). The goal is to see if this treatment helps control the cancer and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have non-small cell lung cancer with an EGFR mutation.
- Your cancer must have spread to the membranes around the brain (leptomeningeal metastasis).
- You can be newly diagnosed with this spread or have had it progress after standard treatments. Up to 3 prior treatment lines are allowed, but more might be possible in a separate group.
- You must be in generally good health (able to do most daily activities) and have adequate organ function.
- You cannot have had high-dose third-generation EGFR targeted therapy or pemetrexed chemotherapy into the spinal fluid before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.